IGM Biosciences, Inc.

NASDAQ:IGMS

9.31 (USD) • At close September 6, 2024
Bedrijfsnaam IGM Biosciences, Inc.
Symbool IGMS
Munteenheid USD
Prijs 9.31
Beurswaarde 552,256,808
Dividendpercentage 0%
52-weken bereik 3.81 - 17.7
Industrie Biotechnology
Sector Healthcare
CEO Mr. Fred M. Schwarzer J.D.
Website https://igmbio.com

An error occurred while fetching data.

Over IGM Biosciences, Inc.

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma

Vergelijkbare Aandelen

Catalyst Pharmaceuticals, Inc. logo

Catalyst Pharmaceuticals, Inc.

CPRX

19.6 USD

TG Therapeutics, Inc. logo

TG Therapeutics, Inc.

TGTX

22.03 USD

DocGo Inc. logo

DocGo Inc.

DCGO

3.63 USD

Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc.

DCPH

25.59 USD

Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp.

AVXL

5.15 USD

Theravance Biopharma, Inc. logo

Theravance Biopharma, Inc.

TBPH

8.01 USD

Editas Medicine, Inc. logo

Editas Medicine, Inc.

EDIT

3.59 USD

Alector, Inc. logo

Alector, Inc.

ALEC

4.85 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)